Mowat-Wilson syndrome (MWS) is an autosomal dominant intellectual disability syndrome characterised by unique facial features and congenital anomalies such as Hirschsprung disease, congenital heart defects, corpus callosum agenesis and urinary tract anomalies. Some cases also present epilepsy, growth retardation and microcephaly. The syndrome is caused by mutations or deletions of the ZEB2 gene at chromosome 2q22-q23. MWS was first described in 1998 and until now approximately 180 cases have been reported worldwide. We report the first three molecularly confirmed Danish cases with MWS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
"I'm not sad anymore, I'm proud to have such a child": The experiences of caregivers of dependents with cerebral palsy living in Greece.
J Pediatr Nurs
January 2025
Department of Nursing, School of Health Rehabilitation Sciences, University of Patras, Nikolaou Gizi 4, Patras, Greece.
Background: People with cerebral palsy are largely dependent on their caregivers, who are most often members of their family. Caring for people with disabilities can be challenging as both dependents and caregivers face problems of social isolation and stigmatization.
Aim: The aim of this study was to understand the experiences of caregivers of dependents with cerebral palsy in Greece.
Application value of split-bolus contrast injection combined with dual-energy CT scanning technology in pediatric CTU imaging.
Eur J Radiol
January 2025
Department of Radiology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China. Electronic address:
Objective: To explore the clinical value of combining split-bolus contrast injection with dual-energy CT(DECT) scanning technology in pediatric computed tomography urography (CTU) imaging.
Methods: A total of 128 children aged 0-17 years were prospectively selected and randomly assigned to three groups: A, B, and C. For Group A, a high-pitch flash mode was employed, where a single bolus of contrast agent was followed by four-phase scanning (noncontrast, cortex, medulla, and excretory phases).
Chlorine-substituted transformation products generated during chlorination of the organophosphorus insecticide disulfoton induce anti-acetylcholine esterase activity.
Chemosphere
January 2025
Faculty of Engineering, Hokkaido University, N13W8, Sapporo, 060-8628, Japan. Electronic address:
Global concern regarding transformation products (TPs) derived from contaminants, including pesticides, in the environment and during water treatment has been growing markedly. In the present study, we investigated the anti-acetylcholinesterase (AChE) activity of an aqueous solution of the organophosphorus insecticide disulfoton, a toxicological endpoint for determining the acceptable daily intake of disulfoton, both in the presence and the absence of metabolism during chlorination. Disulfoton rapidly reacted with free chlorine and completely disappeared within 0.
View Article and Find Full Text PDFMixed Comparative Evaluation of a Training Program Dedicated to Cystic Fibrosis Reference Centers: Protocol for the Pilot Implementation of Shared Decision-Making in the Treatment of Diabetes in Adult Patients With Cystic Fibrosis.
JMIR Res Protoc
January 2025
Cystic Fibrosis Center, Department of Internal Medicine, Hospices Civils de Lyon, Research on Healthcare Performance U1290 Inserm, Lyon 1 University, Lyon, France.
Background: Diabetes affects half of the patients with cystic fibrosis who are aged 30 years and older. Diabetes progresses asymptomatically over a long period of time. Two treatment options are possible: start insulin as soon as cystic fibrosis diagnosis is made with the additional constraints of cystic fibrosis or wait while monitoring the patient's clinical condition and start insulin when diabetes symptoms develop and therefore later.
View Article and Find Full Text PDFThe Pharmacology of Aid in Dying: From Database Analyses to Evidence-Based Best Practices.
J Palliat Med
January 2025
American Clinicians Academy on Medical Aid in Dying, Berkeley, California, USA.
Medical aid in dying is legal in 10 states plus Washington DC, covering 22% of the U.S. population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!